Peri-conception human papillomavirus vaccination exposure and risk of birth defects: a population-based retrospective cohort study

preprint OA: closed
Full text JSON View at publisher
Full text 3,061 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Purpose : Women of childbearing age may receive HPV vaccination during pregnancy, yet evidence on birth defects (BDs) risks remains limited. This study evaluates associations between peri-conception HPV vaccination and BDs. Methods: This population-based retrospective cohort study included pregnancies conceived between March 2018 and December 2021 in Xiamen, China. Propensity score matching based Poisson regression was used to estimate the adjusted relative risk (aRR) of exposure for total BDs and 10 organ system-specific BDs. Two subgroup analyses, including different exposure windows and vaccine valences, six sensitivity analyses, and a negative control analysis were performed. Results: A total of 177,574 pregnancies were included, of which 566 were exposed to the HPV vaccine during the Peri-conception period. The rate of Peri-conception vaccine exposure increased from 0.10% in 2018 to 0.58% in 2021. After 1:4 PSM, peri-conception HPV vaccination was not associated with an increased risk of total BDs (aRR 0.77, 95% confidence interval [CI] 0.42-1.42). Similarly, no significant association was found between HPV vaccination and the risk of 10 organ system-specific BDs. In subgroup analyses, exposure during pre-30 days (aRR 0.59, 95%CI 0.23-1.48) and the first trimester (aRR 0.61, 95%CI 0.14-2.69), exposure to the 4vHPV (aRR 1.25, 95%CI 0.62-2.51) and 9vHPV (aRR 0.57, 95%CI 0.13-2.49) vaccines were not associated with a higher risk of total BDs. All sensitivity and negative control analyses demonstrated the robustness of the results. Conclusions: Our evidence suggests that exposure to the HPV vaccine before and during early pregnancy does not increase the risk of birth defects. This conclusion helps increase the willingness of women of childbearing age to receive HPV vaccination. Trial registration: This study was registered at ClinicalTrials.gov (NCT06180447). Information & Authors Information Version history Peer review timeline Published Pharmacoepidemiology and Drug Safety Version of Record22 Sep 2025Published Copyright This work is licensed under a Non Exclusive No Reuse License. Collection

Keywords

Authors Metrics & Citations Metrics Article Usage 337views 216downloads Citations Download citation Jin Guo, Peng Zhao, Chunrong Liu, et al. Peri-conception human papillomavirus vaccination exposure and risk of birth defects: a population-based retrospective cohort study. Authorea. 03 March 2025. DOI: https://doi.org/10.22541/au.174103926.60657229/v1 DOI: https://doi.org/10.22541/au.174103926.60657229/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-06-21T16:06:39.831647+00:00